APT: Shareholder equity changes reach 1% threshold

APT announced that its shareholder Shenzhen Mindray Technology Holdings and its concerted actor Zhuhai Tongsheng Investment increased their holdings in the company by 2.1647 million shares through block trading on the Shanghai Stock Exchange, accounting for 1.54% of the company's total share capital. After the change in equity, Shenzhen Mindray and its concerted actor's total shareholding increased from 35.2534 million shares to 37.4182 million shares, with the shareholding ratio rising from 25.00% to 26.54%. This increase in holdings complies with relevant laws and regulations and will not result in a change in the company's controlling shareholder and actual controller

This week, the largest increase in margin financing and securities lending balance: Kersen margin balance: 603 million yuan, balance increase: 255.59%; APT margin balance: 131 million yuan, balance increase: 152.07%

APT: Net profit in the first half of 2025 increased by 24.11% year-on-year

APT announced that its operating revenue in the first half of 2025 was 1.214 billion yuan, a year-on-year increase of 21.26%. Net profit was 425 million yuan, a year-on-year increase of 24.11%

APT General Manager Cheng Zhenghui plans to reduce his holdings by no more than 2%

APT's general manager Cheng Zhenghui plans to reduce his holdings by no more than 2.8203 million shares through block trades, accounting for approximately 2% of the company's total share capital. The reduction will take place within three months after the announcement is disclosed, and the total number of shares reduced within any consecutive 90 calendar days will not exceed 2% of the company's total share capital

Huafu Securities: PFA high prosperity track major products domestic accelerated layout for listing

Huafu Securities released a research report indicating that domestic electrophysiology device companies are accelerating their layout of PFA (Pulsed Field Ablation) technology, which is expected to usher in its commercialization in 2025. This technology offers higher tissue selectivity and shorter surgical times compared to traditional methods, with the market size expected to grow from 1.3 billion yuan in 2025 to 16.3 billion yuan in 2032, achieving an average annual growth rate of 43.73%. It is recommended to pay attention to domestic manufacturers with three-dimensional mapping systems, as their products have already achieved international competitiveness in terms of cost control and clinical data